View Cart ()
Your cart is empty
Genetic testing for prostate cancer
Germline testing identifies variants that inform your treatment plan.
Order a testPARP inhibitors recently received FDA approval for the treatment of BRCA- or HRR-mutated mCRPC after previous therapies have failed
Germline testing can identify mCRPC patients with BRCA1, BRCA2, and ATM variants.
Certain genes in the HRR (homologous recombination repair) pathway—BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and/or RAD54L—have been linked to mCRPC and may inform treatment decisions.
Benefits of testing
Genetic information impacts medical management and prevention
When to test
Clear clinical guidelines-based criteria to identify patients at risk
Test options
A curated prostate cancer panel with the option to expand to more cancer genes
Invitae advantage
Fast, affordable, high-quality genetic testing you can count on
Benefits of genetic testing
Genetic testing for prostate cancer can help inform treatment and medical management, as well as aid in the early detection of future cancers.
|
PATIENTS
|
Germline genetic testing may help guide medical management such as:2
|
|
FAMILY MEMBERS
|
|
According to professional society guidelines, germline genetic testing should be considered for prostate cancer patients with at least one of the following criteria:*
- Prostate cancer patients with at least one of the following:
- Intraductal histology
- Regional or metastatic disease
- T3 or T4 disease
- Grade group 4 or 5
- PSA >20 ng/mL
OR
- Prostate cancer patients with at least one of the following family history criteria:
- Brother, father, or multiple family members diagnosed with prostate cancer at <60 years of age or who died of prostate cancer (except clinically localized Grade group 1)
- Family member with a known pathogenic variant
- Three or more cancers on the same side of the family: bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (except clinically localized Grade group 1), small bowel, or urothelial cancer
- Ashkenazi Jewish ancestry
Invitae Prostate Cancer Panel
Invitae’s most comprehensive panel targeting hereditary prostate cancer
Invitae Common Hereditary Cancers Panel
Maximize diagnostic yield for individuals with a personal or family history of mixed cancers affecting a range of organ systems
Not sure which panel is right for your patient?
Consult with one of our board-certified genetic counselors, available Monday through Friday, 5 am to 5 pm Pacific, to identify patients who could benefit from testing and differentiate between tests.
Sponsored genetic testing and counseling for prostate cancer
The Detect Hereditary Prostate Cancer program provides no-charge genetic testing and counseling for individuals diagnosed with prostate cancer, stage II and above.
Learn moreReady to get started? Create an account today.
Create an accountInformed families
Enable cancer prevention and early detection for your patient’s family members.
A positive result in a prostate cancer gene has implications for future cancer risk in multiple clinical areas—not just prostate cancer. Lifetime cancer risks for prostate cancer genes:
For patients who undergo panel or gene testing at Invitae and are found to have a clinically actionable variant, their blood relatives can have up to a 50% risk of having the same variant.
-
Invitae offers family variant testing for all blood relatives of patients who undergo gene or panel testing and have a positive result.
-
Family variant testing involves full analysis of the gene in which the original family member’s variant was identified.
Learn more
Invitae testing is covered by most insurance plans and we will not hold a sample or report while managing insurance claims.
Our $250 patient-pay option and patient assistance program help make high-quality testing accessible.
Option to expand to a larger hereditary cancer panel if needed within 90 days of receiving results, at no additional charge.
Genetic counselors available on demand to help identify patients who could benefit from testing, discuss tough cases, and even counsel your patients directly.
Get started
|
|
1. Request free kits for collecting patient specimens
|
|
|
2. Order a test using Invitae’s HIPAA-compliant online portal or on paper
|
|
|
3. Receive an email when your results are ready (10-21 calendar days, on average)
|
Take the first step by requesting a free specimen collection kit or starting an order today.
Tools for your clinic
Invitae’s reference guides offer direction on when to consider genetic testing and provide management guidelines. We have also created patient resources for you to share with your patients when speaking to them about genetic testing.
Understanding prostate cancer testing
A one-page introduction to genetic testing for hereditary prostate cancer
Risks and references poster
Gene by gene risks for cancer, categorized by organ system
Family history questionnaire
Collect your patient’s full family history to inform management
Have a question or comment? Let us know.
Our team is here to answer your questions about ordering, billing, policies, and logistics as you are becoming familiar with our services.
Subscribe to our mailing list
Stay updated on the latest in prostate cancer. We will send you information on relevant topics once or twice a month.
*These criteria have been adapted from current professional society guidelines. This is not an exhaustive list. Insurance criteria differ across providers. Patients who fit these criteria are not guaranteed to be covered by insurance for genetic testing.
References:
1. Abida W et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making JCO Precis Oncology. Published online May 31, 2017.
2. Nicolosi P, Ledet E, Yang S et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. Published online February 7, 2019.
